{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:05:24Z","timestamp":1790971524914,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2025 \"innovation star\" project for graduate students in Colleges and universities in Gansu Province","award":["CXZX-2025-212"],"award-info":[{"award-number":["CXZX-2025-212"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8226010026"],"award-info":[{"award-number":["8226010026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Project of Gansu Province","award":["22JR11RA053"],"award-info":[{"award-number":["22JR11RA053"]}]},{"name":"CuiYing postgraduate tutor\u2019 training program of Lanzhou University Second Hospital","award":["201710"],"award-info":[{"award-number":["201710"]}]},{"name":"the Key Incubation Project Funds of the second hospital & clinical medical school, lanzhou university","award":["Grant No. 2025-22-zdfy-008"],"award-info":[{"award-number":["Grant No. 2025-22-zdfy-008"]}]},{"DOI":"10.13039\/501100004775","name":"Gansu Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant No. 23JRRA0971"],"award-info":[{"award-number":["Grant No. 23JRRA0971"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Signal Transduction and Activation of Transcription 6 (STAT6) is a key molecule in the Janus Kinase\/Signal Transducer and Activator of Transcription (JAK\/STAT) signaling pathway. Primarily induced by Interleukin-4(IL-4) and Interleukin-13(IL-13), STAT6 undergoes phosphorylation and translocates to the nucleus, where it regulates gene transcription. While the abnormal activation and oncogenic functions of STAT6 in various solid tumors are well documented, its precise biological role in the hematopoietic system has not yet been systematically investigated. Compared with solid tumors, STAT6 activation in hematological malignancies occurs with the Type 2 T helper cell (Th2-type) immune microenvironment that it mediates, which is probably a unique pathogenic mechanism. This review, therefore, delves into the multifunctionality of STAT6 within the hematopoietic system (including viral infection and immune regulation) and hematologic malignancies, as well as its impact on chemotherapy resistance. The aim is to provide a theoretical basis for understanding the biological functions of STAT6 and developing new therapeutic approaches.<\/jats:p>","DOI":"10.1007\/s00277-026-06932-2","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:53:02Z","timestamp":1773654782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["STAT6: Multidimensional analysis from hematopoietic immune regulation to pathogenesis mechanisms and therapeutic targets in hematologic malignancies"],"prefix":"10.1007","volume":"105","author":[{"given":"Shuni","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"6","key":"6932_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/08830185.2024.2395274","volume":"43","author":"M Tolomeo","year":"2024","unstructured":"Tolomeo M, Cascio A (2024) STAT4 and STAT6, their role in cellular and humoral immunity and in diverse human diseases. Int Rev Immunol 43(6):394\u2013418. https:\/\/doi.org\/10.1080\/08830185.2024.2395274","journal-title":"Int Rev Immunol"},{"issue":"3","key":"6932_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12185-023-03692-x","volume":"119","author":"A Benoit","year":"2024","unstructured":"Benoit A, Abraham MJ, Li S et al (2024) STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment. Int J Hematol 119(3):275\u2013290. https:\/\/doi.org\/10.1007\/s12185-023-03692-x","journal-title":"Int J Hematol"},{"issue":"2","key":"6932_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaci.2022.09.028","volume":"151","author":"N Suratannon","year":"2023","unstructured":"Suratannon N, Ittiwut C, Dik WA et al (2023) A germline STAT6 gain-of-function variant is associated with early-onset allergies. J Allergy Clin Immunol 151(2):565\u2013571e9. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.028","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"6932_CR4","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H et al (2022) The JAK-STAT pathway at 30: Much learned, much more to do. Cell 185(21):3857\u20133876. https:\/\/doi.org\/10.1016\/j.cell.2022.09.023","journal-title":"Cell"},{"issue":"5","key":"6932_CR5","doi-asserted-by":"publisher","first-page":"e20221755","DOI":"10.1084\/jem.20221755","volume":"220","author":"M Sharma","year":"2023","unstructured":"Sharma M, Leung D, Momenilandi M et al (2023) Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. J Exp Med 220(5):e20221755. https:\/\/doi.org\/10.1084\/jem.20221755","journal-title":"J Exp Med"},{"key":"6932_CR6","unstructured":"Anonymous Heritable Polygenic Editing: The next Frontier in Genomic Medicine? | Nature. n.d. Available from: https:\/\/www.nature.com\/articles\/s41586-024-08300-4 [Last accessed: 1\/5\/2026]"},{"issue":"1","key":"6932_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaci.2023.01.023","volume":"152","author":"S Baris","year":"2023","unstructured":"Baris S, Benamar M, Chen Q et al (2023) Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6. J Allergy Clin Immunol 152(1):182\u2013194e7. https:\/\/doi.org\/10.1016\/j.jaci.2023.01.023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"6932_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.it.2023.12.003","volume":"45","author":"M Sharma","year":"2024","unstructured":"Sharma M, Suratannon N, Leung D et al (2024) Human germline gain-of-function in STAT6: From severe allergic disease to lymphoma and beyond. Trends Immunol 45(2):138\u2013153. https:\/\/doi.org\/10.1016\/j.it.2023.12.003","journal-title":"Trends Immunol"},{"issue":"7","key":"6932_CR9","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10875-023-01530-7","volume":"43","author":"E Minskaia","year":"2023","unstructured":"Minskaia E, Maimaris J, Jenkins P et al (2023) Autosomal dominant STAT6 gain of function causes severe atopy associated with lymphoma. J Clin Immunol 43(7):1611\u20131622. https:\/\/doi.org\/10.1007\/s10875-023-01530-7","journal-title":"J Clin Immunol"},{"issue":"2","key":"6932_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.cell.2011.09.022","volume":"147","author":"Anonymous","year":"2011","unstructured":"Anonymous (2011) Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 147(2):436\u2013446. https:\/\/doi.org\/10.1016\/j.cell.2011.09.022","journal-title":"Cell"},{"key":"6932_CR11","doi-asserted-by":"publisher","unstructured":"Anonymous (2007) ;110(9):3387\u20133390; https:\/\/doi.org\/10.1182\/blood-2007-03-082511","DOI":"10.1182\/blood-2007-03-082511"},{"issue":"22","key":"6932_CR12","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1182\/bloodadvances.2020002944","volume":"4","author":"D Nann","year":"2020","unstructured":"Nann D, Ramis-Zaldivar JE, M\u00fcller I et al (2020) Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv 4(22):5652\u20135665. https:\/\/doi.org\/10.1182\/bloodadvances.2020002944","journal-title":"Blood Adv"},{"key":"6932_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cellsig.2018.02.016","volume":"46","author":"H Miloudi","year":"2018","unstructured":"Miloudi H, Leroy K, Jardin F et al (2018) STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. Cell Signal 46:76\u201382. https:\/\/doi.org\/10.1016\/j.cellsig.2018.02.016","journal-title":"Cell Signal"},{"key":"6932_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2018.04.002","volume":"63","author":"VJ Weston","year":"2018","unstructured":"Weston VJ, Wei W, Stankovic T et al (2018) Synergistic action of dual IGF1\/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1. Exp Hematol 63:52\u201363e5. https:\/\/doi.org\/10.1016\/j.exphem.2018.04.002","journal-title":"Exp Hematol"},{"issue":"1","key":"6932_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-008-9736-9","volume":"92","author":"S-H Yang","year":"2009","unstructured":"Yang S-H, Lee KS, Kim IS et al (2009) Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: Role of STAT6 activation as prognostic determinant. J Neurooncol 92(1):65\u201371. https:\/\/doi.org\/10.1007\/s11060-008-9736-9","journal-title":"J Neurooncol"},{"issue":"1","key":"6932_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hon.2679","volume":"38","author":"P Mondello","year":"2020","unstructured":"Mondello P, Cuzzocrea S, Arrigo C et al (2020) STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma. Hematol Oncol 38(1):106\u2013110. https:\/\/doi.org\/10.1002\/hon.2679","journal-title":"Hematol Oncol"},{"issue":"8","key":"6932_CR17","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/s41418-023-01194-1","volume":"30","author":"J-H Shi","year":"2023","unstructured":"Shi J-H, Liu L-N, Song D-D et al (2023) TRAF3\/STAT6 axis regulates macrophage polarization and tumor progression. Cell Death Differ 30(8):2005\u20132016. https:\/\/doi.org\/10.1038\/s41418-023-01194-1","journal-title":"Cell Death Differ"},{"issue":"3","key":"6932_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12185-023-03692-x","volume":"119","author":"A Benoit","year":"2024","unstructured":"Benoit A, Abraham MJ, Li S et al (2024) STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment. Int J Hematol 119(3):275\u2013290. https:\/\/doi.org\/10.1007\/s12185-023-03692-x","journal-title":"Int J Hematol"},{"issue":"9","key":"6932_CR19","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood.2020005083","volume":"137","author":"A Pignarre","year":"2021","unstructured":"Pignarre A, Chatonnet F, Caron G et al (2021) ****Plasmablasts derive from CD23\u2013 activated B cells after the extinction of IL-4\/STAT6 signaling and IRF4 induction. Blood 137(9):1166\u20131180. https:\/\/doi.org\/10.1182\/blood.2020005083","journal-title":"Blood"},{"issue":"6","key":"6932_CR20","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.4049\/jimmunol.1402096","volume":"194","author":"K Stokes","year":"2015","unstructured":"Stokes K, LaMarche NM, Islam N et al (2015) Cutting edge: STAT6 signaling in eosinophils is necessary for development of allergic airway inflammation. J Immunol 194(6):2477\u20132481. https:\/\/doi.org\/10.4049\/jimmunol.1402096","journal-title":"J Immunol"},{"issue":"6","key":"6932_CR21","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.4049\/jimmunol.1402096","volume":"194","author":"K Stokes","year":"2015","unstructured":"Stokes K, LaMarche NM, Islam N et al (2015) Cutting edge: STAT6 signaling in eosinophils is necessary for development of allergic airway inflammation. J Immunol 194(6):2477\u20132481. https:\/\/doi.org\/10.4049\/jimmunol.1402096","journal-title":"J Immunol"},{"issue":"10","key":"6932_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/icb.2017.71","volume":"95","author":"S Chevrier","year":"2017","unstructured":"Chevrier S, Kratina T, Emslie D et al (2017) IL4 and IL21 cooperate to induce the high Bcl6 protein level required for germinal center formation. Immunol Cell Biology 95(10):925\u2013932. https:\/\/doi.org\/10.1038\/icb.2017.71","journal-title":"Immunol Cell Biology"},{"issue":"10","key":"6932_CR23","doi-asserted-by":"publisher","first-page":"107737","DOI":"10.1016\/j.jbc.2024.107737","volume":"300","author":"T Arkee","year":"2024","unstructured":"Arkee T, Hornick EL, Bishop GA (2024) TRAF3 regulates STAT6 activation and T-helper cell differentiation by modulating the phosphatase PTP1B. J Biol Chem 300(10):107737. https:\/\/doi.org\/10.1016\/j.jbc.2024.107737","journal-title":"J Biol Chem"},{"issue":"1","key":"6932_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/ijms26010280","volume":"26","author":"X Guan","year":"2024","unstructured":"Guan X, Fury H, Issuree PD et al (2024) The impact of cell-intrinsic STAT6 protein on donor T cell-mediated graft-versus-tumor effect. Int J Mol Sci 26(1):280. https:\/\/doi.org\/10.3390\/ijms26010280","journal-title":"Int J Mol Sci"},{"issue":"4","key":"6932_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW (2023) A timeline of tumour-associated macrophage biology. Nat Rev Cancer 23(4):238\u2013257. https:\/\/doi.org\/10.1038\/s41568-022-00547-1","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"6932_CR26","doi-asserted-by":"publisher","first-page":"eabj7002","DOI":"10.1126\/sciadv.abj7002","volume":"8","author":"S Kamerkar","year":"2022","unstructured":"Kamerkar S, Leng C, Burenkova O et al (2022) Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Sci Adv 8(7):eabj7002. https:\/\/doi.org\/10.1126\/sciadv.abj7002","journal-title":"Sci Adv"},{"issue":"4","key":"6932_CR27","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ijrobp.2017.11.043","volume":"100","author":"OM Rahal","year":"2018","unstructured":"Rahal OM, Wolfe AR, Mandal PK et al (2018) Blocking interleukin (IL)4- and IL13-mediated phosphorylation of STAT6 (Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer. Int J Radiation Oncology*Biology*Physics 100(4):1034\u20131043. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.043","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"22","key":"6932_CR28","doi-asserted-by":"publisher","first-page":"8970","DOI":"10.1021\/acs.jmedchem.5b01321","volume":"58","author":"PK Mandal","year":"2015","unstructured":"Mandal PK, Morlacchi P, Knight JM et al (2015) Targeting the src homology 2 (SH2) domain of signal transducer and activator of transcription 6 (STAT6) with cell-permeable, phosphatase-stable phosphopeptide mimics potently inhibits Tyr641 phosphorylation and transcriptional activity. J Med Chem 58(22):8970\u20138984. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01321","journal-title":"J Med Chem"},{"issue":"5","key":"6932_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.immuni.2010.11.009","volume":"33","author":"A Szanto","year":"2010","unstructured":"Szanto A, Balint BL, Nagy ZS et al (2010) STAT6 transcription factor is a facilitator of the nuclear receptor PPAR\u03b3-regulated gene expression in macrophages and dendritic cells. Immunity 33(5):699\u2013712","journal-title":"Immunity"},{"key":"6932_CR30","doi-asserted-by":"publisher","first-page":"109138","DOI":"10.1016\/j.intimp.2022.109138","volume":"111","author":"Anonymous","year":"2022","unstructured":"Anonymous (2022) Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization. Int Immunopharmacol 111:109138. https:\/\/doi.org\/10.1016\/j.intimp.2022.109138","journal-title":"Int Immunopharmacol"},{"key":"6932_CR31","doi-asserted-by":"publisher","unstructured":"Kamerkar S, Leng C, Burenkova O et al Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Sci Adv n d ;8(7):eabj7002; https:\/\/doi.org\/10.1126\/sciadv.abj7002","DOI":"10.1126\/sciadv.abj7002"},{"key":"6932_CR32","unstructured":"Anonymous Adult Acute Lymphoblastic Leukaemia - PubMed. n.d. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36122035\/ [Last accessed: 9\/29\/2025]"},{"key":"6932_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12964-023-01039-x","volume":"21","author":"R Qin","year":"2023","unstructured":"Qin R, Wang T, He W et al (2023) Jak2\/STAT6\/c-myc pathway is vital to the pathogenicity of philadelphia-positive acute lymphoblastic leukemia caused by P190BCR-ABL. Cell Commun Signal 21:27. https:\/\/doi.org\/10.1186\/s12964-023-01039-x","journal-title":"Cell Commun Signal"},{"issue":"4","key":"6932_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36(4):542\u2013550. https:\/\/doi.org\/10.1016\/j.immuni.2012.03.014","journal-title":"Immunity"},{"issue":"1","key":"6932_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41419-025-07981-7","volume":"16","author":"S Sun","year":"2025","unstructured":"Sun S, Cheng Y, Huang X et al (2025) Targeted deprivation of STAT6 sensitizes acute lymphoblastic leukemia cells to cytarabine in vivo and in vitro: Clinical implications. Cell Death Dis 16(1):669. https:\/\/doi.org\/10.1038\/s41419-025-07981-7","journal-title":"Cell Death Dis"},{"issue":"8","key":"6932_CR36","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00262-020-02835-x","volume":"70","author":"S Traxel","year":"2021","unstructured":"Traxel S, Lehmann J, Richard S et al (2021) Support of BCP-ALL-cells by autologous bone marrow th-cells involves induction of AID expression but not widespread AID off-target mutagenesis. Cancer Immunol Immunother 70(8):2275\u20132289. https:\/\/doi.org\/10.1007\/s00262-020-02835-x","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"6932_CR37","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","volume":"131","author":"A Mottok","year":"2018","unstructured":"Mottok A, Steidl C (2018) Biology of classical hodgkin lymphoma: Implications for prognosis and novel therapies. Blood 131(15):1654\u20131665. https:\/\/doi.org\/10.1182\/blood-2017-09-772632","journal-title":"Blood"},{"issue":"5","key":"6932_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/PAI.0000000000001277","volume":"33","author":"D Bay\u00e7elebi","year":"2025","unstructured":"Bay\u00e7elebi D, Yildiz \u015e, Yildiz L et al (2025) STAT6 can be used in the diagnosis of hodgkin lymphoma: There are differences in expression among subtypes. Appl Immunohistochem Mol Morphology 33(5):277. https:\/\/doi.org\/10.1097\/PAI.0000000000001277","journal-title":"Appl Immunohistochem Mol Morphology"},{"key":"6932_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40164-018-0100-2","volume":"7","author":"MA Hjort","year":"2018","unstructured":"Hjort MA, Hov H, Abdollahi P et al (2018) Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical hodgkin lymphoma and promotes survival and migration. Exp Hematol Oncol 7:8. https:\/\/doi.org\/10.1186\/s40164-018-0100-2","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"6932_CR40","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2018-08-871293","volume":"133","author":"L von Hoff","year":"2019","unstructured":"von Hoff L, K\u00e4rgel E, Franke V et al (2019) Autocrine LTA signaling drives NF-\u03baB and JAK-STAT activity and myeloid gene expression in hodgkin lymphoma. Blood 133(13):1489\u20131494. https:\/\/doi.org\/10.1182\/blood-2018-08-871293","journal-title":"Blood"},{"issue":"5","key":"6932_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41379-019-0428-0","volume":"33","author":"C Van Slambrouck","year":"2020","unstructured":"Van Slambrouck C, Huh J, Suh C et al (2020) Diagnostic utility of STAT6YE361 expression in classical hodgkin lymphoma and related entities. Mod Pathol 33(5):834\u2013845. https:\/\/doi.org\/10.1038\/s41379-019-0428-0","journal-title":"Mod Pathol"},{"issue":"4","key":"6932_CR42","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/cancers13040884","volume":"13","author":"EAM Zijtregtop","year":"2021","unstructured":"Zijtregtop EAM, van der Strate I, Beishuizen A et al (2021) Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical hodgkin lymphoma. Cancers (Basel) 13(4):884. https:\/\/doi.org\/10.3390\/cancers13040884","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6932_CR43","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","volume":"112","author":"D Buglio","year":"2008","unstructured":"Buglio D, Georgakis GV, Hanabuchi S et al (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in hodgkin lymphoma cell lines. Blood 112(4):1424\u20131433. https:\/\/doi.org\/10.1182\/blood-2008-01-133769","journal-title":"Blood"},{"issue":"19","key":"6932_CR44","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.3390\/cancers15194866","volume":"15","author":"M Donzel","year":"2023","unstructured":"Donzel M, Pesce F, Trecourt A et al (2023) Molecular characterization of primary mediastinal large B-cell lymphomas. Cancers (Basel) 15(19):4866. https:\/\/doi.org\/10.3390\/cancers15194866","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6932_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12185-023-03692-x","volume":"119","author":"A Benoit","year":"2024","unstructured":"Benoit A, Abraham MJ, Li S et al (2024) STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment. Int J Hematol 119(3):275\u2013290. https:\/\/doi.org\/10.1007\/s12185-023-03692-x","journal-title":"Int J Hematol"},{"issue":"9","key":"6932_CR46","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/s41375-022-01641-x","volume":"36","author":"M Mentz","year":"2022","unstructured":"Mentz M, Keay W, Strobl CD et al (2022) PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia 36(9):2281\u20132292. https:\/\/doi.org\/10.1038\/s41375-022-01641-x","journal-title":"Leukemia"},{"issue":"1","key":"6932_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/15592294.2020.1786317","volume":"16","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zhang F, Fu H et al Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma. Epigenetics n d ;16(1):28\u201344; https:\/\/doi.org\/10.1080\/15592294.2020.1786317","journal-title":"Epigenetics n d"},{"issue":"3","key":"6932_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cytogfr.2006.01.004","volume":"17","author":"D Hebenstreit","year":"2006","unstructured":"Hebenstreit D, Wirnsberger G, Horejs-Hoeck J et al (2006) Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 17(3):173\u2013188. https:\/\/doi.org\/10.1016\/j.cytogfr.2006.01.004","journal-title":"Cytokine Growth Factor Rev"},{"issue":"18","key":"6932_CR49","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1182\/bloodadvances.2022008355","volume":"6","author":"GT Los-de Vries","year":"2022","unstructured":"Los-de Vries GT, Stevens WBC, van Dijk E et al (2022) Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III\/IV. Blood Adv 6(18):5482\u20135493. https:\/\/doi.org\/10.1182\/bloodadvances.2022008355","journal-title":"Blood Adv"},{"issue":"21","key":"6932_CR50","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1182\/bloodadvances.2021005284","volume":"6","author":"S Crouch","year":"2022","unstructured":"Crouch S, Painter D, Barrans SL et al (2022) Molecular subclusters of follicular lymphoma: A report from the united kingdom\u2019s haematological malignancy research network. Blood Adv 6(21):5716\u20135731. https:\/\/doi.org\/10.1182\/bloodadvances.2021005284","journal-title":"Blood Adv"},{"issue":"4","key":"6932_CR51","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","volume":"125","author":"M Yildiz","year":"2015","unstructured":"Yildiz M, Li H, Bernard D et al (2015) Activating STAT6 mutations in follicular lymphoma. Blood 125(4):668\u2013679. https:\/\/doi.org\/10.1182\/blood-2014-06-582650","journal-title":"Blood"},{"issue":"18","key":"6932_CR52","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1182\/bloodadvances.2023010779","volume":"7","author":"DA Russler-Germain","year":"2023","unstructured":"Russler-Germain DA, Krysiak K, Ramirez C et al (2023) Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Adv 7(18):5524\u20135539. https:\/\/doi.org\/10.1182\/bloodadvances.2023010779","journal-title":"Blood Adv"},{"issue":"4","key":"6932_CR53","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41375-025-02525-6","volume":"39","author":"Q Shao","year":"2025","unstructured":"Shao Q, Bedi K, Malek IA et al (2025) STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4\/STAT6\/RRAGD\/mTOR signaling in follicular lymphoma. Leukemia 39(4):899\u2013908. https:\/\/doi.org\/10.1038\/s41375-025-02525-6","journal-title":"Leukemia"},{"issue":"6","key":"6932_CR54","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","volume":"114","author":"O Ritz","year":"2009","unstructured":"Ritz O, Guiter C, Castellano F et al (2009) Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 114(6):1236\u20131242. https:\/\/doi.org\/10.1182\/blood-2009-03-209759","journal-title":"Blood"},{"issue":"19","key":"6932_CR55","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.3390\/cancers15194866","volume":"15","author":"M Donzel","year":"2023","unstructured":"Donzel M, Pesce F, Trecourt A et al (2023) Molecular characterization of primary mediastinal large B-cell lymphomas. Cancers (Basel) 15(19):4866. https:\/\/doi.org\/10.3390\/cancers15194866","journal-title":"Cancers (Basel)"},{"issue":"11","key":"6932_CR56","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1038\/leu.2008.85","volume":"22","author":"O Ritz","year":"2008","unstructured":"Ritz O, Guiter C, Dorsch K et al (2008) STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma. Leukemia 22(11):2106\u20132110. https:\/\/doi.org\/10.1038\/leu.2008.85","journal-title":"Leukemia"},{"issue":"6","key":"6932_CR57","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","volume":"114","author":"O Ritz","year":"2009","unstructured":"Ritz O, Guiter C, Castellano F et al (2009) Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 114(6):1236\u20131242. https:\/\/doi.org\/10.1182\/blood-2009-03-209759","journal-title":"Blood"},{"key":"6932_CR58","unstructured":"Anonymous Targeting of Somatic Hypermutation | Nature Reviews Immunology. n.d. Available from: https:\/\/www.nature.com\/articles\/nri1896 [Last accessed: 9\/12\/2025]"},{"issue":"6","key":"6932_CR59","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","volume":"114","author":"O Ritz","year":"2009","unstructured":"Ritz O, Guiter C, Castellano F et al (2009) Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 114(6):1236\u20131242. https:\/\/doi.org\/10.1182\/blood-2009-03-209759","journal-title":"Blood"},{"key":"6932_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.humpath.2022.12.003","volume":"131","author":"JH Paik","year":"2023","unstructured":"Paik JH, Koh J, Han B et al (2023) Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: A multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression. Hum Pathol 131:47\u201360. https:\/\/doi.org\/10.1016\/j.humpath.2022.12.003","journal-title":"Hum Pathol"},{"issue":"8","key":"6932_CR61","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/PAS.0000000000002062","volume":"47","author":"A Satou","year":"2023","unstructured":"Satou A, Takahara T, Yamashita D et al (2023) Diagnostic utility of STAT6 and pSTAT6 immunohistochemistry for distinguishing classic hodgkin lymphoma and peripheral T-cell lymphoma with hodgkin and reed-sternberg\u2013like cells. Am J Surg Pathol 47(8):897. https:\/\/doi.org\/10.1097\/PAS.0000000000002062","journal-title":"Am J Surg Pathol"},{"issue":"15","key":"6932_CR62","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1182\/blood.2019004725","volume":"136","author":"AM Gaydosik","year":"2020","unstructured":"Gaydosik AM, Queen DS, Trager MH et al (2020) Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma. Blood 136(15):1748\u20131759. https:\/\/doi.org\/10.1182\/blood.2019004725","journal-title":"Blood"},{"issue":"11","key":"6932_CR63","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/jid.2014.206","volume":"134","author":"X Wu","year":"2014","unstructured":"Wu X, Schulte BC, Zhou Y et al (2014) Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol 134(11):2814\u20132822. https:\/\/doi.org\/10.1038\/jid.2014.206","journal-title":"J Invest Dermatol"},{"issue":"4","key":"6932_CR64","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1182\/blood-2002-02-0475","volume":"101","author":"M Kleinhans","year":"2003","unstructured":"Kleinhans M, Tun-Kyi A, Gilliet M et al (2003) Functional expression of the eotaxin receptor CCR3 in CD30\u2009+\u2009cutaneous T-cell lymphoma. Blood 101(4):1487\u20131493. https:\/\/doi.org\/10.1182\/blood-2002-02-0475","journal-title":"Blood"},{"issue":"1","key":"6932_CR65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ajpath.2019.09.005","volume":"190","author":"SD Turner","year":"2020","unstructured":"Turner SD, Inghirami G, Miranda RN et al (2020) Cell of origin and immunologic events in the pathogenesis of breast implant-associated anaplastic large-cell lymphoma. Am J Pathol 190(1):2\u201310. https:\/\/doi.org\/10.1016\/j.ajpath.2019.09.005","journal-title":"Am J Pathol"},{"issue":"2","key":"6932_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/asj\/sjac234","volume":"43","author":"ME Kadin","year":"2023","unstructured":"Kadin ME, Morgan J, Wei W et al (2023) CD30 regulation of IL-13\u2013STAT6 pathway in breast implant\u2013associated anaplastic large cell lymphoma. Aesthet Surg J 43(2):137\u2013146. https:\/\/doi.org\/10.1093\/asj\/sjac234","journal-title":"Aesthet Surg J"},{"issue":"1","key":"6932_CR67","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12935-025-03757-3","volume":"25","author":"T Zhang","year":"2025","unstructured":"Zhang T, Wei D, Zhan Y et al (2025) Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner. Cancer Cell Int 25(1):129. https:\/\/doi.org\/10.1186\/s12935-025-03757-3","journal-title":"Cancer Cell Int"},{"issue":"5","key":"6932_CR68","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","volume":"178","author":"PJ Murray","year":"2007","unstructured":"Murray PJ (2007) The JAK-STAT signaling pathway: Input and output integration. J Immunol 178(5):2623\u20132629. https:\/\/doi.org\/10.4049\/jimmunol.178.5.2623","journal-title":"J Immunol"},{"issue":"15","key":"6932_CR69","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.3390\/cancers13153724","volume":"13","author":"G Veltri","year":"2021","unstructured":"Veltri G, Silvestri C, Gallingani I et al (2021) Ruxolitinib as a novel therapeutic option for poor prognosis T-LBL pediatric patients. Cancers (Basel) 13(15):3724. https:\/\/doi.org\/10.3390\/cancers13153724","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6932_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41419-025-07981-7","volume":"16","author":"S Sun","year":"2025","unstructured":"Sun S, Cheng Y, Huang X et al (2025) Targeted deprivation of STAT6 sensitizes acute lymphoblastic leukemia cells to cytarabine in vivo and in vitro: Clinical implications. Cell Death Dis 16(1):669. https:\/\/doi.org\/10.1038\/s41419-025-07981-7","journal-title":"Cell Death Dis"},{"key":"6932_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2018.04.002","volume":"63","author":"VJ Weston","year":"2018","unstructured":"Weston VJ, Wei W, Stankovic T et al (2018) Synergistic action of dual IGF1\/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1. Exp Hematol 63:52\u201363e5. https:\/\/doi.org\/10.1016\/j.exphem.2018.04.002","journal-title":"Exp Hematol"},{"key":"6932_CR72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2018.04.002","volume":"63","author":"VJ Weston","year":"2018","unstructured":"Weston VJ, Wei W, Stankovic T et al (2018) Synergistic action of dual IGF1\/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1. Exp Hematol 63:52\u201363e5. https:\/\/doi.org\/10.1016\/j.exphem.2018.04.002","journal-title":"Exp Hematol"},{"issue":"10","key":"6932_CR73","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","volume":"20","author":"Y Hao","year":"2014","unstructured":"Hao Y, Chapuy B, Monti S et al (2014) Selective JAK2 inhibition specifically decreases hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 20(10):2674\u20132683. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6932_CR74","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","volume":"112","author":"D Buglio","year":"2008","unstructured":"Buglio D, Georgakis GV, Hanabuchi S et al (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in hodgkin lymphoma cell lines. Blood 112(4):1424\u20131433. https:\/\/doi.org\/10.1182\/blood-2008-01-133769","journal-title":"Blood"},{"issue":"9","key":"6932_CR75","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/s41375-022-01641-x","volume":"36","author":"M Mentz","year":"2022","unstructured":"Mentz M, Keay W, Strobl CD et al (2022) PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia 36(9):2281\u20132292. https:\/\/doi.org\/10.1038\/s41375-022-01641-x","journal-title":"Leukemia"},{"issue":"1","key":"6932_CR76","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-024-03068-x","volume":"43","author":"M Durand","year":"2024","unstructured":"Durand M, Cabaud Gibouin V, Duplomb L et al (2024) A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical hodgkin lymphoma. J Exp Clin Cancer Res 43(1):148. https:\/\/doi.org\/10.1186\/s13046-024-03068-x","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"6932_CR77","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.3324\/haematol.2015.135418","volume":"101","author":"DE Spaner","year":"2016","unstructured":"Spaner DE, Wang G, McCaw L et al (2016) Activity of the janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: Results of a phase II trial. Haematologica 101(5):e192\u2013e195. https:\/\/doi.org\/10.3324\/haematol.2015.135418","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06932-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06932-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06932-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:09:14Z","timestamp":1781640554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06932-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6932"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06932-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Review does not require ethical approval from the Ethics Committee of Lanzhou University Second Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"statement: No potential conflict of interest was reported by the author(s).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}